Previous 10 | Next 10 |
Syneos Health ( NASDAQ: SYNH ) rose 7.5% on a report that the contract research organization has started a new effort to sell itself. Syneos ( SYNH ) hired Bank of America and Centerview as its financial advisors to explore a new set of talks with potential buyers, including i...
Summary Flat Q4 and full-year top-line growth, offset by reasonable upsides in the commercial solutions segment. The company hasn't delivered a return on invested capital above the WACC hurdle, limiting value creation for shareholders. Guidance points to further contraction in earni...
The following slide deck was published by Syneos Health, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Syneos Health, Inc. 2022 Q4 - Results - Earnings Call Presentation
Syneos Health, Inc. (SYNH) Q4 2022 Earnings Conference Call February 16, 2023, 8:00 AM ET Company Participants Ronnie Speight - Senior Vice President, Investor Relations Michelle Keefe - Chief Executive Officer Jason Meggs - Chief Financial Officer Michael Brooks -...
Syneos Health press release ( NASDAQ: SYNH ): Q4 Non-GAAP EPS of $1.23 beats by $0.03 . Revenue of $1.36B (-0.7% Y/Y) beats by $80M . Clinical Solutions revenue of $1,023.3 million decreased 2.1% on a reported basis and increased 0.7% on a constant currency basis. Comm...
Revenue for the fourth quarter of $1,359.9 million decreased 1.0% on a reported basis and increased 1.7% on a constant currency basis year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $470.1 million for the f...
Syneos Health ( NASDAQ: SYNH ) is scheduled to announce Q4 earnings results on Thursday, February 16th, before market open. The consensus EPS Estimate is $1.20 (-18.9% Y/Y) and the consensus Revenue Estimate is $1.28B (-6.6% Y/Y). Over the last 2 years, SYNH has beaten EPS e...
Syneos Health ( NASDAQ: SYNH ) ticked up 0.12% amid activist speculation following a 13F filing. Goldman Sachs added more than 3 million shares of Syneos Health ( SYNH ) in Q4 after reporting owning almost 730K in Q3, Gordon Haskett's Don Bilson highlighted in a note earlier. ...
Syneos Health ( NASDAQ: SYNH ) shed ~5% on Monday, marking the biggest intraday loss since November after JPMorgan downgraded the contract research organization citing concerns about the company's Q4 results scheduled for this week. Expecting a "challenging" fourth quarter, the an...
MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, prior to its earnings call at 8:00 ...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...